<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168195">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01946399</url>
  </required_header>
  <id_info>
    <org_study_id>Ozurdex RVO 2013</org_study_id>
    <nct_id>NCT01946399</nct_id>
  </id_info>
  <brief_title>Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF</brief_title>
  <official_title>Dexamethasone Intravitreal Implant for Retinal Vein Occlusion Associated Macular Edema After Treatment Failure With Anti-VEGF Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Research Institute, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Retinal Consultants of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Retina Vitreous Associates Medical Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West Coast Retina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Research Institute, LLC</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if Ozurdex implant can offer an effective treatment for macular edema
      associated with retinal vein occlusion when treatment with intravitreal Avastin, Lucentis,
      or Eylea have not demonstrated a significant response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine whether Ozurdex implant can offer an efficacious alternative for treatment of
      macular edema in the setting of retinal vein occlusion when treatment with intravitreal
      bevacizumab (Avastin),ranibizumab (Lucentis), and/or aflibercept (Eylea) have not
      demonstrated significant response.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in best-corrected Snellen visual acuity following initiation of Ozurdex therapy</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomic/angiographic improvement in macular edema as evaluated by OCT and fluorescein angiography</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Retinal Vein Occlusion (RVO)</condition>
  <condition>Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ozurdex implant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravitreal injection of Ozurdex implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex implant</intervention_name>
    <description>Intravitreal injection of Dexamethasone implant</description>
    <arm_group_label>Ozurdex implant</arm_group_label>
    <other_name>Dexamethasone implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients with Retinal Vein Occlusion (RVO) with available initial imaging and
        documented treatment failure with bevacizumab, ranibizumab, or aflibercept. Treatment
        failure is defined as lack of anatomic improvement (persistent intraretinal cystic
        changes/macular edema with central subfield thickness greater than 250 microns on
        time-domain OCT or greater than 275 microns on spectral domain OCT) with lack of visual
        improvement (less than 2 lines of visual gain by Snellen acuity), despite 3 to 6
        intravitreal anti-VEGF treatments over the preceding 6 months.

        Exclusion Criteria:

          -  Co-existing or pre-existing macular degeneration, diabetic macular edema,  or other
             confounding disease processes

          -  Interval surgical intervention, such as cataract surgery, that may confound visual
             outcomes.

          -  Pregnancy

          -  Coexisting conditions that would represent relative or absolute contraindications
             usage of ozurdex implant, including:

          -  Ocular or periocular infections (including viral disease of the cornea and
             conjunctiva such as active epithelial herpes simplex keratitis, vaccinia, varicella,
             mycobacterial infection, and fungal diseases)

          -  Advanced glaucoma

          -  Aphakic eyes with rupture or missing posterior lens capsule

          -  Eyes with anterior chamber intraocular lens and missing posterior lens capsule

          -  Patients with known hypersensitivity to components of this product
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaurav K Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Retina Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 16, 2013</lastchanged_date>
  <firstreceived_date>September 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Research Institute, LLC</investigator_affiliation>
    <investigator_full_name>Rhonda Weeks</investigator_full_name>
    <investigator_title>Gaurav K. Shah, MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
